comparemela.com

Latest Breaking News On - Tumour growth kinetics - Page 1 : comparemela.com

Immutep (IMMP) Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

Immutep (IMMP) Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care. | March 31, 2023

Immutep Announces Publication of TACTI-002 Abstract at ESMO s European Lung Cancer Congress 2022

Immutep Announces Publication of TACTI-002 Abstract at ESMO s European Lung Cancer Congress 2022
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Immutep announces publication of TACTI-002 abstract at ESMO s European Lung Cancer Congress 2022

Immutep announces publication of TACTI-002 abstract at ESMO’s European Lung Cancer Congress 2022  New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in second line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients Combination continues.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.